Common Stock Offering. Title of Securities: Class B Common Stock, par value $0.001 per share, of the Issuer (the “Class B Common Stock”) Ticker / Exchange: VIAC / The Nasdaq Global Select Market. Number of Shares of Class B Common Stock Offered: 20,000,000 shares of Class B Common Stock. Option to Purchase Additional Shares: 3,000,000 additional shares of Class B Common Stock. Last Reported Sale Price of the Class B Common Stock on The Nasdaq Global Select Market on March 23, 2021: $91.25 per share. Public Offering Price of the Class B Common Stock: $85.00 per share. Underwriting Discount: $1.38125 per share. Net Proceeds: The net proceeds from the Common Stock Offering, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $1.67 billion (or approximately $1.93 billion if the underwriters exercise their option in full to purchase additional shares of Class B Common Stock). CUSIP / ISIN: 00000X000 / US92556H2067 Joint Book-Running Managers: Xxxxxx Xxxxxxx & Co. LLC X.X. Xxxxxx Securities LLC Citigroup Global Markets Inc. Xxxxxxx Xxxxx & Co. LLC Mizuho Securities USA LLC Xxxxxxx Xxxxxxxx Shank & Co., LLC Co-Managers: BNP Paribas Securities Corp. RBC Capital Markets, LLC SMBC Nikko Securities America, Inc. TD Securities (USA) LLC SG Americas Securities, LLC MUFG Securities Americas Inc. CastleOak Securities, L.P. Xxxxxx X. Xxxxxxx & Company, Inc. Academy Securities, Inc. X. Xxxxxxx & Co., LLC Xxxxx Fargo Securities, LLC BNY Mellon Capital Markets, LLC Intesa Sanpaolo S.p.A.
Common Stock Offering. Title of Securities: Common Stock, par value $.01 per share, of the Issuer. Shares Offered: 9,100,000 (10,465,000 if the over-allotment option is exercised in full). NYSE Last Reported Sale Price on May 21, 2009: $22.13 per share of the Issuer’s Common Stock. Price to Public: $22.00 per share. Underwriting Discount per Share: $0.935 per share. Proceeds, Before Expenses, to the Issuer: $191.6915 million (approximately $220.445 million if the over-allotment option is exercised in full).
Common Stock Offering. Shares Offered: 10,000,000 shares of Common Stock (or 11,500,000 shares if the underwriters exercise their option to purchase an additional 1,500,000 shares of Common Stock in full). Common Stock Outstanding: 113,278,670 shares immediately after the Common Stock Offering (or 114,778,670 shares if the underwriters exercise their option to purchase additional shares of Common Stock in full). Public Offering Price: $25.00 per share of Common Stock Transaction Size: $250 million in gross proceeds (or up to $287.5 million if the underwriters’ option is exercised in full), before deducting underwriting discounts and the Issuer’s estimated offering expenses. Underwriting Discount: $1.50 per share of Common Stock.
Common Stock Offering. Title of Securities Common Stock, par value $1.00 per share, of the Company (the “Common Stock”) Number of Shares of Common Stock Offered 9,000,000 (or 10,350,000 if the underwriters of the Common Stock Offering exercise their option to purchase up to 1,350,000 additional shares of Common Stock in full) Common Stock Public Offering Price $46.25 per share of Common Stock $416,250,000 in aggregate (or $478,687,500 if the underwriters of the Common Stock Offering exercise their option to purchase up to 1,350,000 additional shares of Common Stock in full) Underwriting Discounts and Commissions $1.71125 per share of Common Stock $15,401,250.00 in aggregate (or $17,711,437.50 if the underwriters of the Common Stock Offering exercise their option to purchase up to 1,350,000 additional shares of Common Stock in full) The underwriters of the Common Stock Offering propose to offer the shares of Common Stock to dealers at the Common Stock Public Offering Price less a concession not in excess of $1.02680 per share of Common Stock. Estimated Net Proceeds to the Company from the Common Stock Offering The Company estimates that it will receive net proceeds of approximately $400 million from the sale of Common Stock in the Common Stock Offering after deducting the Underwriting Discounts and Commissions and estimated offering expenses. The Company estimates that it will receive net proceeds of approximately $460 million if the underwriters of the Common Stock Offering exercise their option to purchase additional shares of Common Stock in full. Book-Running Managers Credit Suisse Securities (USA) LLC Xxxxx Fargo Securities, LLC Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx Incorporated Xxxxxx Xxxxxxx & Co. LLC Co-Managers X.X. Xxxxxx Securities LLC RBC Capital Markets, LLC Xxxxxx, Xxxxxxxx & Company, Incorporated Xxxxxx X. Xxxxx & Co., X.X. Xxxxxx & Co. Xxxxxx X. Xxxxxxx & Company, Inc. CUSIP for the Common Stock 505597 104 ISIN for the Common Stock US5055971049
Common Stock Offering. Offering Size: 125,000,000 Shares (100% Primary) Overallotment Option (15%): 18,750,000 Shares (100% Primary) Public Offering Price per Share: $4.55 Last Sale Price (6/7/06): $4.55 Proceeds per Share, before expenses, to Level 3: $4.3452 Trade Date: 6/7/2006 Settlement Date: 6/13/2006 CUSIP: 52729N 10 0 Issuer: Level 3 Communications, Inc. Offering Size: $300,000,000 Overallotment Option (15%): $45,000,000 Issue Price: 100% of principal amount Maturity: June 15, 2012 Interest Rate: 3.5% Interest Payment Dates: June 15 and December 15, beginning December 15, 2006 Conversion Premium: 20% Conversion Price: $5.46 Last Sale Price (6/7/06): $4.55 Conversion Rate: 183.1502 Optional Redemption by Issuer: Beginning June 15, 2010, at specified redemption prices set forth below, plus accrued and unpaid interest, if any, to the redemption date. The following prices are for notes redeemed during the 12-month period commencing on June 15 of the years set forth below, and are expressed as percentages of principal amount: 2010 101.17 % 2011 100.58 % Make Whole Premium upon Change of Control: If certain changes in control occur as specified in the Preliminary Prospectus Supplement relating to the notes and the notes are converted in connection with such transaction, the conversion rate will be increased by the number of additional shares set forth in the table below for each $1,000 principal amount of notes in the case of stock prices on the effective date of such change in control transaction between $4.55 and $50.00 (subject to adjustment upon certain events). The amount of the increase in the applicable conversion rate, if any, will be based on the date on which the change in control becomes effective and the price paid per share of common stock in the transaction constituting the change in control. $4.55 36.6300 36.6300 36.6300 36.6300 36.6300 5.00 30.9107 27.6440 23.9440 19.5353 16.8498 6.00 22.7335 19.2489 15.1353 9.8467 0.0000 7.00 17.9817 14.6954 10.8424 6.0174 0.0000 8.00 14.9523 11.9736 8.5466 4.4408 0.0000 10.00 11.3823 8.9649 6.2974 3.2480 0.0000 15.00 7.4364 5.8279 4.0800 2.1505 0.0000 20.00 5.5807 4.3677 3.0595 1.6154 0.0000 25.00 4.4788 3.4979 2.4508 1.2943 0.0000 50.00 2.2854 1.7670 1.2325 0.6548 0.0000 Proceeds per $1,000 Principal Amount, before expenses, to Level 3: $975 Trade Date: 6/7/2006 Settlement Date: 6/13/2006 CUSIP: 52729N BK 0 Joint Leads (both Common & Convert): Credit Suisse & Xxxxxx Xxxxxxx Co-Managers (Common only): Bear Xxxxxxx & Co. Inc.,...
Common Stock Offering. Title of Securities: Common stock, par value $1.00 per share, of the Issuer. Shares Offered and Sold: 135,000,000 shares (or a total of 155,250,000 shares if the underwriters exercise their option to purchase up to 20,250,000 additional shares of the Issuer’s common stock in full). Initial Price to Public: $5.15 per share / $695,250,000 total (excluding the underwriters’ option to purchase up to 20,250,000 additional shares of the Issuer’s common stock). Underwriting Discount: $0.23175 per share / $31,237,582 total (excluding the underwriters’ option to purchase up to 20,250,000 additional shares of the Issuer’s common stock). Proceeds, Before Expenses, to the Issuer: $4.91825 per share / $664,012,418 total (excluding the underwriters’ option to purchase up to 20,250,000 additional shares of the Issuer’s common stock). The Underwriters will not receive any discount on any shares purchased by the Issuer’s officers. The total underwriting discount and the total proceeds, before expenses, to the Issuer are based upon the discount received by the underwriters for shares of common stock, other than the 210,000 shares of common stock to be purchased by such officers. The total underwriting discount and total proceeds, before expenses, to the Issuer reflects the fact that the Issuer will receive the full initial price to public of the shares purchased by such officers.
Common Stock Offering. Issuer Mesa Laboratories, Inc. Shares Offered 375,000 shares of Common Stock (or, if the underwriters of the Common Stock Offering fully exercise their option to purchase additional shares of Common Stock, 431,250 shares of Common Stock). Public Offering Price $210.00 per share of Common Stock. Ticker / Exchange MLAB / The Nasdaq Global Select Market (“NASDAQ”). Underwriting Discount $12.60 per share of Common Stock, and $4,725,000 in the aggregate (or $5,433,750 in the aggregate, if the underwriters of the Common Stock Offering fully exercise their option to purchase additional shares of Common Stock). Trade Date August 8, 2019. Settlement Date August 12, 2019. Use of Proceeds The Issuer estimates that the net proceeds from the Common Stock Offering will be approximately $73.9 million (or approximately $85.0 million, if the underwriters of the Common Stock Offering fully exercise their option to purchase additional shares of Common Stock), after deducting the underwriting discounts and other estimated offering expenses payable by the Issuer.
Common Stock Offering. Issuer: Kindred Healthcare, Inc., a Delaware corporation (“Kindred”). Ticker / Exchange: KND / New York Stock Exchange (“NYSE”). Pricing Date: November 19, 2014. Settlement Date: November 25, 2014. Title of Securities: Common stock, par value $0.25 per share, of Kindred (“Common Stock”).
Common Stock Offering. Shares of Common Stock Offered: 70,000,000 shares (80,500,000 shares if the underwriters elect to exercise their option to purchase additional shares in full). Common Stock To be Outstanding Immediately after the Common Stock Offering: 578,885,530 shares (589,385,530 shares if the underwriters in the Common Stock Offering elect to exercise their option to purchase additional shares in full).
Common Stock Offering. Title of securities: Common stock, par value $0.20 per share Shares issued: 101,781,170 Over-allotment option: 15,267,176 shares Outstanding common shares after offering: 510,597,592 shares of common stock (or 525,864,768 shares if the underwriters exercise their over-allotment option in full). The number of shares of the Company’s common stock to be outstanding immediately after the closing of this offering is based on 414,116,096 shares and 408,816,422 shares of the Company’s common stock outstanding as of September 30, 2007 and December 24, 2007, respectively. This number excludes an aggregate of approximately 36,690,629 shares of the Company’s common stock issuable upon exercise of options outstanding as of December 24, 2007, at a weighted average exercise price of $39.93 per share, of which options to purchase 25,065,524 shares were exercisable as of that date at a weighted average exercise price of $34.96 per share. This number also excludes any shares of the Company’s common stock issuable upon conversion of the Company’s 7.25% mandatory convertible preferred stock, assuming the successful completion of the Mandatory Convertible Preferred Stock Offering, and shares issuable under outstanding restricted stock grants. This number also does not include any share reduction related to physically settling the Company’s equity forward contract. Net proceeds after underwriting discount and estimated expenses: Approximately $1.939 billion (approximately $2.231 billion if the over-allotment option is exercised in full). Net proceeds for equity forward purchase contract settlement: Approximately $2.0 billion of the net proceeds from this offering and the concurrent Mandatory Convertible Preferred Stock Offering. Capitalization: See below Last sale (on December 27, 2007): $19.65 Public offering price per share: $19.65 Underwriting discount per share: $0.5895 Aggregate underwriting discount: $60.0 million Selling concession per share: $0.3537 Offering expenses, excluding underwriting discount (estimated): $1.15 million Pricing date: December 27, 2007 Trade date: December 28, 2007 Settlement date: We expect that the delivery of the common stock will be made against payment therefor on December 31, 2007, which will be the first business day following the trade date of the common stock (such settlement cycle being herein referred to as “T+1”). Under Rule 15c6-1 under the Exchange Act, trades in the secondary market generally are required to settle in three business...
